SHISA4: A Potential Drug Target and Biomarker (G149345)

Target Name: SHISA4

NCBI ID: G149345

SHISA4

SHISA4: A Potential Drug Target and Biomarker

SHISA4, or transmembrane protein 58, is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

SHISA4 is a transmembrane protein that is expressed in various tissues throughout the body, including the brain, pancreas, and blood vessels. It is made up of 116 amino acids and has a calculated molecular weight of 14.5 kDa. The protein is characterized by a N -terminal cytoplasmic domain, a transmembrane region, and a C-terminal extracellular domain.

The SHISA4 protein is involved in various physiological processes in the body, including cell signaling, metabolism, and inflammation. It is a key regulator of the T-cell receptor (TCR), which is responsible for cell signaling and immune responses. The TCR is a transmembrane protein that is involved in the development and activation of T cells, which are a crucial part of the immune system.

SHISA4 has been shown to play a role in the regulation of TCR function. Studies have shown that SHISA4 can interact with the TCR and regulate its activity. This interaction between SHISA4 and TCR suggests that SHISA4 may be a potential drug target for TCR-related diseases.

In neurodegenerative diseases, SHISA4 has been shown to be involved in the development and progression of neurodegeneration. For example, studies have shown that SHISA4 is expressed in the brains of individuals with Alzheimer's disease and that its levels are decreased in the brains of individuals with Parkinson's disease. Additionally, SHISA4 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is important for neurotransmission.

In autoimmune disorders, SHISA4 has been shown to play a role in the development and progression of autoimmune diseases. For example, studies have shown that SHISA4 is expressed in the tissues of individuals with rheumatoid arthritis and that its levels are decreased in the blood of individuals with rheumatoid arthritis. Additionally, SHISA4 has been shown to be involved in the regulation of immune cell function, which is important for the development and progression of autoimmune diseases.

SHISA4 has also been shown to have potential as a biomarker for various diseases. For example, studies have shown that SHISA4 is expressed in the blood samples of individuals with cancer and that its levels are decreased in the blood of individuals with cancer. Additionally, SHISA4 has been shown to be involved in the regulation of cell cycle progression, which is important for the development and progression of cancer.

In conclusion, SHISA4 is a protein that has been identified as a potential drug target and biomarker in various diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of SHISA4 in various diseases and to develop new treatments based on its unique properties.

Protein Name: Shisa Family Member 4

The "SHISA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHISA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets